Untreated growth hormone deficiency explains premature mortality in patients with hypopituitarism.
Untreated growth hormone deficiency (GHD) might explain the increased mortality reported in patients with hypopituitarism. These statistics appear to be largely attributable to cardiovascular disease. Differences in fibrinolytic activity regulators, together with dyslipidaemias, abdominal obesity and raised blood pressure in hypopituitarism might explain this increased risk. There is growing evidence that treatment with growth hormone (GH) can rectify most of the cardiovascular abnormalities associated with GHD. The reported improved psychosocial well-being in response to GH treatment may also be important in lowering risk in this group of patients.
Bengtsson
B A
BA
Research Centre for Endocrinology and Metabolism, Sahlgrenska University Hospital, Göteborg, Sweden.
D002318:Cardiovascular Diseases / Q000209:etiology / Q000401:mortality; D005340:Fibrinogen / Q000378:metabolism; D019382:Human Growth Hormone / Q000172:deficiency* / Q000627:therapeutic use; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications; D006973:Hypertension; D007018:Hypopituitarism / Q000097:blood* / Q000150:complications / Q000188:drug therapy / Q000401:mortality*; D007328:Insulin / Q000378:metabolism; D007333:Insulin Resistance; D009765:Obesity / Q000150:complications; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D011788:Quality of Life; D011994:Recombinant Proteins / Q000627:therapeutic use
D007328:Insulin; D017395:Plasminogen Activator Inhibitor 1; D011994:Recombinant Proteins; D019382:Human Growth Hormone; D005340:Fibrinogen